https://www.selleckchem.com/pr....oducts/anacetrapib-m
The median overall survival was 15.1 (95% confidence interval [CI] = 11.1-24.8) months. On bivariate analysis, chemotherapy improved overall survival (p = 0.01) while radiation therapy (p = 0.07) and extent of resection (p = 0.48) did not. On multivariate analysis, older patients (hazard ratio [HR] = 1.07, CI = 1.03-1.11, p less then 0.01) and Charlson/Deyo scores of ≥1 versus 0 (HR = 3.47, CI = 1.40-8.60, p less then 0.01) had significantly increased mortality risk following surgery. In particular, the Charlson/Deyo score i
Curtir
Comentario
Compartilhar
